- Home
- CATX vs IPHA Comparison
CATX vs IPHA Comparison
Compare CATX & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- IPHA
- Stock Information
- Founded
- CATX 1983
- IPHA 1999
- Country
- CATX United States
- IPHA France
- Employees
- CATX N/A
- IPHA N/A
- Industry
- CATX Medical/Dental Instruments
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- CATX Health Care
- IPHA Health Care
- Exchange
- CATX Nasdaq
- IPHA Nasdaq
- Market Cap
- CATX 182.9M
- IPHA 160.1M
- IPO Year
- CATX N/A
- IPHA 2019
- Fundamental
- Price
- CATX $2.34
- IPHA $2.44
- Analyst Decision
- CATX Strong Buy
- IPHA Strong Buy
- Analyst Count
- CATX 10
- IPHA 1
- Target Price
- CATX $13.89
- IPHA $11.00
- AVG Volume (30 Days)
- CATX 619.9K
- IPHA 33.6K
- Earning Date
- CATX 05-12-2025
- IPHA 03-27-2025
- Dividend Yield
- CATX N/A
- IPHA N/A
- EPS Growth
- CATX N/A
- IPHA N/A
- EPS
- CATX N/A
- IPHA N/A
- Revenue
- CATX $1,454,000.00
- IPHA $20,831,349.00
- Revenue This Year
- CATX N/A
- IPHA $209.83
- Revenue Next Year
- CATX N/A
- IPHA $83.96
- P/E Ratio
- CATX N/A
- IPHA N/A
- Revenue Growth
- CATX 1.40
- IPHA N/A
- 52 Week Low
- CATX $1.60
- IPHA $1.29
- 52 Week High
- CATX $19.10
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- CATX 51.17
- IPHA 73.73
- Support Level
- CATX $2.18
- IPHA $2.22
- Resistance Level
- CATX $2.65
- IPHA $2.34
- Average True Range (ATR)
- CATX 0.16
- IPHA 0.15
- MACD
- CATX 0.02
- IPHA 0.04
- Stochastic Oscillator
- CATX 56.25
- IPHA 84.40
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.